GSK to provide adjuvant for Clover’s COVID-19 vaccine, Phase I could start in three months

Clover, a Chengdu, China-based biopharmaceutical company, Monday announced a collaboration with GlaxoSmithKline to advance development of a COVID-19 vaccine candidate.

Sichuan Clover Biopharmaceuticals Inc. has access to samples from infected patients, strong relationships with Chinese regulatory authorities, and access to clinical trial sites, Joshua Liang, Clover’s chief strategy officer, told BioCentury. Vaccine and mAb developers in the U.S. and Europe have had difficulty accessing samples from COVID-19 patients. ...